TY - JOUR
T1 - Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation
AU - Sellebjerg, F.
AU - Krakauer, M.
AU - Hesse, D.
AU - Ryder, L.P.
AU - Alsing, I.
AU - Jensen, P.E.
AU - Koch-Henriksen, N.
AU - Svejgaard, A.
AU - Sorensen, P. Soelberg
AU - Sellebjerg, Finn Thorup
AU - Krakauer, M
AU - Hesse, D
AU - Ryder, L P
AU - Alsing, I
AU - Jensen, P E H
AU - Koch-Henriksen, Nils
AU - Svejgaard, Anja
AU - Sørensen, Per Soelberg
PY - 2009
Y1 - 2009
N2 - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.
AB - Neutralizing antibodies (NAbs) occur in a proportion of multiple sclerosis (MS) patients treated with interferon (IFN)-beta. NAbs impair the effect of treatment. The biological effect of IFN-beta can be measured as the induction of the myxovirus resistance protein A (MxA) molecule. However, other markers could be more sensitive for evaluating the response to IFN-beta. We used DNA array analysis to identify genes that are strongly induced in blood cells by IFN-beta, and measured their expression in MS patients with different NAb levels.
U2 - 10.1111/j.1468-1331.2009.02716.x
DO - 10.1111/j.1468-1331.2009.02716.x
M3 - Journal article
SN - 1351-5101
VL - 16
SP - 1291
EP - 1298
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 12
ER -